[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE255906T1 - Antikörper gegen cd40 - Google Patents

Antikörper gegen cd40

Info

Publication number
ATE255906T1
ATE255906T1 AT94927340T AT94927340T ATE255906T1 AT E255906 T1 ATE255906 T1 AT E255906T1 AT 94927340 T AT94927340 T AT 94927340T AT 94927340 T AT94927340 T AT 94927340T AT E255906 T1 ATE255906 T1 AT E255906T1
Authority
AT
Austria
Prior art keywords
antibodies against
binding
ligand
monoclonal antibodies
specifically bind
Prior art date
Application number
AT94927340T
Other languages
English (en)
Inventor
William C Fanslow Iii
Jodee Zappone
Mark Alderson
Richard J Armitage
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE255906T1 publication Critical patent/ATE255906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94927340T 1993-10-01 1994-09-02 Antikörper gegen cd40 ATE255906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13054193A 1993-10-01 1993-10-01
PCT/US1994/009984 WO1995009653A1 (en) 1993-10-01 1994-09-02 Antibodies to cd40

Publications (1)

Publication Number Publication Date
ATE255906T1 true ATE255906T1 (de) 2003-12-15

Family

ID=22445171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927340T ATE255906T1 (de) 1993-10-01 1994-09-02 Antikörper gegen cd40

Country Status (15)

Country Link
US (1) US5801227A (de)
EP (1) EP0724456B1 (de)
JP (1) JP3675819B2 (de)
KR (1) KR960704576A (de)
AT (1) ATE255906T1 (de)
AU (1) AU686230B2 (de)
CA (1) CA2172376C (de)
DE (1) DE69433406T2 (de)
DK (1) DK0724456T3 (de)
ES (1) ES2211884T3 (de)
FI (1) FI961285A (de)
NO (1) NO961151D0 (de)
NZ (1) NZ273504A (de)
PT (1) PT724456E (de)
WO (1) WO1995009653A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
KR19980702490A (ko) * 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
DK1082141T3 (da) * 1998-05-23 2005-12-05 Univ Leiden Medical Ct CD40-bindende molekyler og CTL-peptider til behandling af tumorer
AU4685900A (en) 1999-04-30 2000-11-17 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1975182A1 (de) 2000-02-01 2008-10-01 PanGenetics B.V. CD40-bindende und APC-aktivierende Moleküle
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
EP1372724A2 (de) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Verwendung von immunregulatorischen antikörpern zur behandlung von neoplastischen erkrankungen
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
DK1391464T3 (da) * 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoklonalt antistof
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20070098717A1 (en) * 2003-11-04 2007-05-03 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
RU2442606C2 (ru) * 2005-11-01 2012-02-20 Новартис Аг Применение анти-cd40-антител
CN101325970B (zh) * 2005-11-01 2013-08-14 诺华有限公司 抗cd40抗体的应用
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP3556774B1 (de) 2011-03-11 2024-01-03 Beth Israel Deaconess Medical Center Inc. Anti-cd40-antikörper und verwendungen davon
JP6125489B2 (ja) 2011-04-29 2017-05-10 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
ES2879552T3 (es) 2012-10-30 2021-11-22 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
DK3303395T3 (da) 2015-05-29 2020-01-27 Abbvie Inc Anti-cd40-antistoffer og anvendelser deraf
KR20180044422A (ko) 2015-09-04 2018-05-02 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
EP4393937A1 (de) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroidverbindung und konjugat davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules

Also Published As

Publication number Publication date
FI961285A0 (fi) 1996-03-20
CA2172376C (en) 2008-11-18
JP3675819B2 (ja) 2005-07-27
AU7681994A (en) 1995-05-01
WO1995009653A1 (en) 1995-04-13
EP0724456B1 (de) 2003-12-10
ES2211884T3 (es) 2004-07-16
NZ273504A (en) 1997-12-19
DE69433406D1 (de) 2004-01-22
DE69433406T2 (de) 2004-10-07
EP0724456A4 (de) 1997-07-02
AU686230B2 (en) 1998-02-05
NO961151L (no) 1996-03-21
JPH09504169A (ja) 1997-04-28
US5801227A (en) 1998-09-01
PT724456E (pt) 2004-04-30
CA2172376A1 (en) 1995-04-13
FI961285A (fi) 1996-03-20
DK0724456T3 (da) 2004-04-13
KR960704576A (ko) 1996-10-09
NO961151D0 (no) 1996-03-21
EP0724456A1 (de) 1996-08-07

Similar Documents

Publication Publication Date Title
ATE255906T1 (de) Antikörper gegen cd40
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
DE69233735D1 (de) Bindungsdomänen des Delta-proteins
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
DE69535133D1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
MX347883B (es) Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
DE69128543D1 (de) Monoklonale antikörper der maus
DK0640135T3 (da) Immunoglobulinbindende proteiner, der er afledt af protein L, og anvendelser af disse
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
ATE368225T1 (de) Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
IS6143A (is) Peptíð úr TT veiruröð og einsérhæfð mótefni, sem bindast TT veirunni
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
DE68912772D1 (de) Monoklonaler antikörper gegen entero-viren.
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0724456

Country of ref document: EP

REN Ceased due to non-payment of the annual fee